Friday, March 31, 2023
Clinical Advances in
Evidence shows that there are disparities in multiple myeloma (MM) treatment between clinical trials and real-world outcomes. Awareness of potential practice-changing new data in frontline, maintenance, and relapsed/refractory (RR) MM, new treatment pathways, as well as emerging treatment challenges will provide guidance on how to achieve deep and longer responses based on both clinical and social needs. This collection provides important information and discussions among experts on the latest advances in MM, with the ultimate goal of improving patient outcomes.
Supported by an independent educational grant from
Steering Committee Chair
University of Newcastle
Newcastle, United Kingdom
University of Athens
Athens, Greece
University Hospital Würzburg
Würzburg, Germany
Emory University
Atlanta, Georgia, United States
University Hospital of Salamanca
Salamanca, Spain
University Hospital of Nantes
Nantes, France
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Amgen Inc.; Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Celgene Corporation; Onyx; Takeda Pharmaceuticals North America, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals
Received grants for clinical research from: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Janssen Pharmaceuticals
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Celgene Corporation; Takeda Pharmaceuticals North America, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Celgene Corporation; EDO mundipharma; GlaxoSmithKline; Janssen Pharmaceuticals; Pharmamar; Seattle Genetics, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Adaptive; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals; Takeda Pharmaceuticals North America, Inc.